deltatrials
Terminated NCT00122265

Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer

Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal RT for Prostate Cancer

Sponsor: AHS Cancer Control Alberta

Conditions Prostate Cancer
Updated 6 times since 2017 Last updated: Feb 24, 2016 Started: Apr 30, 2003 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This observational or N/A phase trial investigates Prostate Cancer and is currently terminated or withdrawn. AHS Cancer Control Alberta leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated

  5. Apr 2018 — Jun 2018 [monthly]

    Terminated

    Phase: NA → None

▶ Show 1 earlier version

  1. Jan 2017 — Apr 2018 [monthly]

    Terminated NA

    First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AHS Cancer Control Alberta
Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Edmonton, Canada